　　 食品伙伴网讯2024�?�?1日，�?a href='//www.sqrdapp.com/news/tag_1377.html' class='zdbq' title='欧盟食品安全局相关食品资讯' target='_blank'>欧盟食品安全局＇�a href='//www.sqrdapp.com/news/tag_10.html' class='zdbq' title='EFSA相关食品资讯' target='_blank'>EFSA）消息，欧盟营养、新型食品和食物过敏源（NDA）研究小组就明日叶汁（ashitaba sap）作为新型食品的安全性发表科学意见�

　　部分原文报道如下９�/div>

　　Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on ashitaba sap as a novel food (NF) pursuant to Regulation (EU) 2015/2283. Ashitaba sap is collected from harvested stems of Angelica keiskei plants. The principal co nstituents of the sap with regard to the safety assessment are chalco nes (1%�C2.25%) and furanocoumarins (< 0.01%). The applicant proposed to use the NF in food supplements at a maximum dose of 780 mg per day. The target population is adults excluding pregnant and lactating women. Taking into co nsideration the composition of the NF and the proposed uses, the composition of the NF is not nutritio nally disadvantageous. There are no co ncerns regarding genotoxicity of the NF. ba sed on a 90-day oral toxicity study performed with the product as intended to be placed on the market (30% ashitaba sap powder and 70% cyclodextrins), the Panel establishes a safe dose of 0.5 mg/kg body weight (bw) per day for the product as it is intended to be placed on the market. For the target population, i.e. adults, this safe dose correspo nds to 35 mg per day of the product as it is intended to be placed on the market and 137 mg per day of the NF, which is lower than the use level proposed by the applicant. The Panel co ncludes that the NF is safe for the target population at intake levels up to 137 mg per day.